Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744059 | 0.85 | KMT2A (0.35) | KMT2AMEN1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4746853 | 0.84 | CNR2 (0.36) | KMT2AMEN1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4746051 | 0.81 | KMT2A (0.37) | KMT2AMEN1NR3C1PGRNR3C2 | |
| SCHEMBL13855995 | 0.80 | FABP4 (0.59) | KMT2AMEN1FABP4NR3C1PGR | |
| SCHEMBL4746087 | 0.79 | KMT2A (0.53) | KMT2AMEN1FABP4NR3C1PGR | |
| SCHEMBL4746850 | 0.79 | FABP4 (0.38) | KMT2AMEN1FABP4LMNAPOLB | |
| SCHEMBL14080567 | 0.79 | FABP4 (0.58) | KMT2AMEN1FABP4NR3C1PGR | |
| SCHEMBL14080568 | 0.79 | FABP4 (0.58) | KMT2AMEN1FABP4NR3C1PGR | |
| SCHEMBL14080648 | 0.79 | FABP4 (0.58) | KMT2AMEN1FABP4NR3C1PGR | |
| SCHEMBL4788843 | 0.79 | ALDH1A1 (0.34) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112251-A1 | CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES | PROGEN PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112251-A1 | CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES | PROGEN PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007106554-A2 | TREATMENT AND PREVENTION OF VASCULAR HYPERPLASIA USING POLYAMINE AND POLYAMINE ANALOG COMPOUNDS | PROGEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | SRM, SMS, PCNA | KMT2A 562/4885MEN1 100/4885FABP4 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.